Inclusion Criteria:

1. An written, voluntary informed consent form must be completed prior to beginning any
study procedure.

2. Patients >/= 18 years of age.

3. Histologically documented diagnosis of non-small cell lung cancer.

4. At least one measurable site of disease that is amenable to biopsy. Lesion must be at
least 20 mm in the longest diameter by spiral computed tomography (CT) or 20 mm with
conventional techniques according to RECIST. Lesion must not have been previously
irradiated.

5. Performance status 0-1 (Eastern Cooperative Oncology Group (ECOG))

6. Patients must have adequate hepatic, renal, and bone marrow function, defined as the
following: (1) total bilirubin < 1.5 * upper limit of normal (ULN); (2) serum
glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase
(SGPT) < 2.5 * UNL; (3) creatinine < 1.5 * ULN; (4) ANC > 1.5 * 10^9/L; (5) platelets
> 100 * 10^9/L.

7. Female patients of childbearing potential must have negative pregnancy test within 7
days before initiation of study drug dosing. Postmenopausal women must be amenorrheic
for at least 12 months to be considered of non-childbearing potential. Male and
female patients of reproductive potential must agree to employ an effective barrier
method of birth control throughout the study and for up to 3 months following
discontinuation of study drug.

8. Patients who have received one prior systemic chemotherapy treatment (not including
biologic agents e.g. gefitinib, lonafarnib).

9. Patients who were originally diagnosed with earlier stage Non-small-cell lung
carcinoma (NSCLC) & were treated with curative intent (i.e. pts who have received
induction chemotherapy (platinum-based doublet) prior to definitive radiation or
surgery) but then develop recurrent or metastatic disease & are then treated with a
platinum-based doublet for frontline metastatic therapy are still eligible for this
study. This is as long as they have not been exposed to docetaxel during any point of
their therapy. Once patients have been diagnosed with metastatic or recurrent
disease, they may only have received one platinum-based therapy.

Exclusion Criteria:

1. Patient has received any other investigational agents within 30 days of first day of
study drug dosing.

2. Patient is < 5 years free of another primary malignancy except: if the other primary
malignancy is not currently clinically significant nor requiring active intervention,
or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in
situ. Existence of any other malignant disease is not allowed.

3. Patient with Grade III/IV cardiac problems as defined by the New York Heart
Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6
months of study)

4. Female patients who are pregnant or breast-feeding.

5. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled
diabetes, chronic renal disease, or active uncontrolled infection).

6. Patient has a known untreated or unstable brain metastasis.

7. Patient has known chronic liver disease (i.e., chronic active hepatitis, and
cirrhosis).

8. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection. HIV
patients are at much greater risk of infection when receiving highly myelosuppressive
agents (docetaxel and imatinib) and for safety reasons are not eligible for this
trial.

9. Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C)
prior to study entry, unless the disease is rapidly progressing.

10. Patient previously received radiotherapy to >/= 25 % of the bone marrow

11. Patient had a major surgery within 2 weeks prior to study entry.

12. Patient with any significant history of non-compliance to medical regimens or with
inability to grant reliable informed consent.

13. Patients must agree not to use herbal remedies or other over-the-counter biologics
(i.e. shark cartilage)

14. History of hypersensitivity to docetaxel or other taxane therapy.

15. History of severe hypersensitivity reaction to drugs formulated with polysorbate 80.

16. Prior exposure to imatinib mesylate.

17. Prior exposure to docetaxel systemic therapy for this NSCLC malignancy.

18. Patient treated with more than 1 prior systemic chemotherapy (not including biologic
agents e.g. gefitinib, lonafarnib)

19. Participation in an investigational trial within the past 30 days.

20. Patients taking therapeutic levels of warfarin. However, patients receiving 1 mg
daily for catheter related anticoagulation are eligible for the study.

21. Prior pericardial effusion requiring intervention such as pericardiocentesis or
pericardial window.